易瑞沙联合P方案治疗晚期肺腺癌的临床观察.docVIP

NP方案序贯易瑞沙治疗晚期肺腺癌的临床观察 456550 河南林州 林州市人民医院放疗科 牛永健 [摘要] 背景与目的：晚期肺腺癌患者的治疗是多以化疗为主的全身治疗，目前尚无标准的治疗方案。本研究旨在观察晚期肺腺癌在常规NP方案化疗（4-6周期）后序贯易瑞沙（靶向治疗）治疗对患者生存率及生存质量的影响。方法：2009年1月—2011年1月经病理证实符合入选标准的15例晚期肺腺癌患者，接受NP方案化疗（4-6周期）后序贯易瑞沙治疗，治疗结束后按照实体瘤疗效评价标准（RECIST 1.0）评价疗效，化疗结束后3-4周开始口服易瑞沙。结果：15例患者中，13例患者按规定完成4周期以上方案，总体PR5例，SD4例，PD4例，RR为38.4﹪（5/13），DCR69.2%(9/13)，中位PFS6月,中位OS为11.8月。与易瑞沙相关的不良反应以皮疹、腹泻多见，其中多为0、Ⅰ、Ⅱ级，Ⅲ、Ⅳ级少见。结论：NP方案序贯易瑞沙治疗晚期肺腺癌可提高一定的生存率及生存质量，安全有效，临床收益率高，是临床上值得推广的有应用前景的治疗方法。 [关键词] NP方案；易瑞沙；晚期肺腺癌；联合化疗 Clinical effect of NP regimen in combination with sequential Iressa in the treatment of advanced adenocarcinoma of the lung Niu Yong-jian, the People’s Hospital of Linzhou city, Linzhou 456550,China 【Abstract】Objctive: The treatment of advanced adenocarcinoma of the lung is dependent on the chemotherapy of all body, up to now there is still no standard regimen of therapy.This study aims at observing the survival rate and quality on NP regimen（4～6 cycles）in combination with sequential Iressa in the treatment of advanced adenocarcinoma of the lung. Methods:From Jan.2009 to Jan.2011, a total of 15 patients with advanced adenocarcinoma of the lung received Iressa and chemotherapy.The efficacy was estimated by RICIST evaluation standard every 4～6 cycles, Iressa was taken orally after 3～4 weeks from chemotherapy end. Results: In a total of 15 patients, 13 patients had received chemotherapy beyond 4 cycles。5 patients were PR,4 patients were SD, 4 patients were PD,the objective response rate was 38.4﹪,and disease control rate was 69.2%. The PFS was 6.0 months and OS was 11.8 months. The most commonly adverse events of Iressa were rash and diarrhea. Most were degree 0、Ⅰ、Ⅱ and degree Ⅲ、Ⅳ were rare. Conclusion: NP regimen in combination with sequential Iressa in the treatment of advanced adenocarcinoma of the lung could increase the certain survival rate and quality,It was effective and safety of combined Iressa with chemotherapy sequential Iressa in the treatment of advanced aden